"You folks have done a terrific job over the years, but we have to get prices down for a lot of reasons. We have no choice. For Medicare, Medicaid, we have to get the prices way down."
President Donald Trump, speaking at a meeting with the Pharmaceutical Research and Manufacturers of America, together with the CEOs of several major U.S. biopharma companies

"We were hoping to achieve at least a 24-hour improvement. That's what everybody agreed would be clinically and commercially meaningful. What we hit was 17 hours. It is not good enough, but it's not that far from the 24 we were looking for, and we do believe that with higher doses and potentially a somewhat different study design, that is achievable."
Linda Grais, CEO, Ocera Therapeutics Inc., on the ammonia-scavenging agent OCR-002 (ornithine phenylacetate), which missed its endpoint in the phase IIb STOP-HE trial in hospitalized patients with hepatic encephalopathy

"The other really great power of the technology is the application of novel chemistry to expand the chemical matter in a much more focused way than had been possible in the past. So I think we will have very rich and efficient small libraries that can do exceptional things. We intend to illustrate that you can do things with this that you can't do with traditional approaches. There's a lot of enthusiasm."
Tom Daniel, executive chairman, Vividion Therapeutics Inc., which received a $50 million series A investment
to advance its proteome-wide ligand and target discovery platform